Aricept, Donepezil

Aricept, Donepezil Newswire

Comprehensive Real-Time News Feed for Aricept, Donepezil (generic).

Results 1 - 20 of 89 in Aricept, Donepezil (generic)

  1. Adamas trading below IPO priceRead the original story

    Monday Apr 14 | Seeking Alpha

    In yet another example of the recent struggles of biotechs, recent IPO Adamas Pharmaceutics exchanges hands for $13.40/share, down 16% from its initial price of $16 and down 22% from its opening day high of $17.24.

    Comment?

  2. Emeryville's Adamas Pharmaceuticals bounces around after $48 million IPORead the original story

    Thursday Apr 10 | The Campbell Reporter

    The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18.

    Comment?

  3. Adamas Pharma Rises After IPO Raises $48MRead the original story

    Friday Apr 11 | Pharmaceutical Processing

    The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18.

    Comment?

  4. Donepezil and life expectancy in Alzheimer's disease: A...Read the original story

    Thursday Apr 10 | BioMed Central

    Cholinesterase inhibitors such as donepezil have the effect of delaying progression of Alzheimer's disease , but their effect on life expectancy is unclear.

    Comment?

  5. Adamas Pharma wobble after IPO prices at $16 per share, at low end of expected rangeRead the original story

    Thursday Apr 10 | Nanaimo Daily News

    The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18.

    Comment?

  6. Here's What Can Help With Agitation in Alzheimer'sRead the original story w/Photo

    Friday Apr 4 | Psychology Today

    Anybody who has a loved one with dementia and has assisted with her care knows how difficult the disease can be for everybody involved.

    Comment?

  7. Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual PropertyRead the original story

    Monday Mar 31 | Hispanic Business

    The licensing of AF710B complements Anavex's existing pipeline in Alzheimer's disease, which is the company's core competency and includes lead clinical candidate ANAVEX PLUS.

    Comment?

  8. What If You Could Learn As Fast As A Child?Read the original story w/Photo

    Wednesday Mar 26 | Refinery 29

    Say what you will about those overbearing tiger parents who put their kids in Mandarin class before they can even walk.

    Comment?

  9. Anavex reports predicted clinical effect of both ANAVEX 2-73 and...Read the original story

    Monday Mar 31 | Medical News Today

    Anavex reports predicted clinical effect of both ANAVEX 2-73 and ANAVEX PLUS in a humanized cortical cognitive model for Alzheimer's disease Anavex Life Sciences Corp., a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system and various types of cancer , has announced ... (more)

    Comment?

  10. Toward a Pill That Helps Us Learn as Fast as BabiesRead the original story w/Photo

    Friday Mar 28 | The Atlantic

    Scientists are using mood drugs to return the adult's brain to an earlier stage of development.

    Comment?

  11. Cilostazol Add-On Therapy in Patients with Mild Dementia Receiving Donepezil: A Retrospective StudyRead the original story

    Saturday Mar 22 | CiteULike

    Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in the elderly.

    Comment?

  12. Anavex Life Sciences Corp. Successfully Closes $10 Million Financing...Read the original story

    Wednesday Mar 19 | BioSpace

    Anavex Life Sciences Corp. Successfully Closes $10 Million Financing To Initiate Phase 1b/2a Alzheimer's Clinical Trial Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial NEW YORK, March 19, 2014 -- Anavex Life Sciences Corp. , a clinical stage biopharmaceutical company developing novel drug ... (more)

    Comment?

  13. Shorts Are Piling Into These Stocks. Should You Be Worried?Read the original story

    Monday Mar 17 | The Motley Fool

    The best thing about the stock market is that you can make money in either direction .

    Comment?

  14. Anavex Announces $10 Million Private Placement of Convertible DebenturesRead the original story

    Monday Mar 17 | Hispanic Business

    In addition, the investors will receive warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate.

    Comment?

  15. Biogen, Eisai Join Up in Alzheimer's Drug PactRead the original story

    Mar 6, 2014 | The Motley Fool

    Cambridge, Mass.-based Biogen today cut a wide-ranging deal with Japan's Eisai .

    Comment?

  16. Forest Files NDA For Alzheimer's Combination TherapyRead the original story

    Mar 5, 2014 | Pharmaceutical Online

    Forest Laboratories announced it has submitted an NDA to the FDA for the fixed dose combination of memantine HCL extended release and donepezil HCL as treatment for moderate to severe dementia related to Alzheimer's disease.

    Comment?

  17. Forest Submits NDA for Memantine ER and Donepezil Fixed-Dose Combination for Alzheimer's DiseaseRead the original story

    Mar 4, 2014 | Drugs.com

    NEW YORK & EMERYVILLE, Calif., Tuesday, March 4, 2014 8:00 am EST -- --Forest Laboratories, Inc. , a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, and Adamas Pharmaceuticals Inc., a privately held specialty pharmaceutical company, announced Forest's submission of a New Drug Application to ... (more)

    Comment?

  18. Forest Labs Submits NDA for Alzheimer's Drug CombinationRead the original story

    Mar 4, 2014 | The Motley Fool

    The company announced that it, together with privately held Adamas Pharmaceuticals, has submitted a New Drug Application to the Food and Drug Administration for a fixed-dose combination of memantine HCl extended release, and donepezil HCl.

    Comment?

  19. Forest Labs and Adamas Pharmaceuticals Sumbit NDA for Alzheimer's Disease TreatmentRead the original story

    Mar 4, 2014 | Pharmaceutical Processing

    Forest Laboratories and Adamas Pharmaceuticals have jointly announced Forest's submission of a New Drug Application to the Food and Drug Administration for a fixed-dose combination of memantine HCl extended release and donepezil HCl for the treatment of moderate to severe dementia of the Alzheimer's type.

    Comment?

  20. Forest Laboratories and Adamas Pharmaceuticals Announce Foresta s...Read the original story

    Mar 4, 2014 | Business Wire

    NEW YORK & EMERYVILLE, Calif.-- --Forest Laboratories, Inc. , a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, and Adamas Pharmaceuticals Inc., a privately held specialty pharmaceutical company, announced Forest's submission of a New Drug Application to the Food and Drug Administration for a ... (more)

    Comment?